Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
Cognitive impairment and cortical degeneration in neuromyelitis optica.
Company restores access to multiple sclerosis drug after pressure from neurologists.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Immunology 2013
Roche reports positive studies of MabThera given by subcutaneous injection
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
[Nicolau syndrome after administration of glatiramer acetate].
Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Effects of an aqueous extract of North American ginseng on MOG((35-55))-induced EAE in mice.
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
Puma, but not noxa is essential for oligodendroglial cell death.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
GEMSP: A New Therapeutic Approach to Multiple Sclerosis.
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
Extoxnet (extension toxicology network), 4-aminopyridine
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
8th FENS Forum of Neuroscience
IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.

Pages